Professor Andrew Pollard, the head of the Oxford Vaccine Group and chief investigator into the trial of the vaccine, has become the third patient to receive the new jab. <br /> Report by Thomasl. Like us on Facebook at http://www.facebook.com/itn and follow us on Twitter at http://twitter.com/itn
